One study identified that NT-proBNP was a key predictor of 3-year major adverse limb events (MALEs), with its inclusion in a machine learning model improving predictive accuracy for adverse outcomes in PAD patients [36]. This evidence concerns the gene NPPB and peripheral arterial disease.